Montelukast Sodium CAS NO 151767-02-1 Inquire about Montelukast Sodium
Tecoland supplies Montelukast Sodium bulk active pharmaceutical ingredient (API) to the pharmaceutical industry. Our Montelukast Sodium is manufactured by cGMP compliant facility. Welcome to contact us for further details including current DMF status for the product and up to date regulatory status of the manufacturing facility. We look forward to assisting you with your research and development projects.
What is Montelukast Sodium?
Montelukast sodium, the active ingredient in SINGULAIR, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT1 receptor.
Montelukast sodium is described chemically as [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid, monosodium salt.
What is the mechanism of action?
Montelukast inhibits bronchoconstriction due to antigen challenge. Montelukast is a selective leukotriene receptor antagonist of the cysteinyl leukotriene CysLT 1 receptor. The cysteinyl leukotrienes (LTC 4, LTD 4, LTE 4) are products of arachidonic acid metabolism that are released from various cells, including mast cells and eosinophils. They bind to cysteinyl leukotriene receptors (CysLT) found in the human airway. Binding of cysteinyl leukotrienes to leukotriene receptors has been correlated with the pathophysiology of asthma, including airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process, factors that contribute to the signs and symptoms of asthma. Montelukast binding to the CysLT 1 receptor is high-affinity and selective, preferring the CysLT 1 receptor to other pharmacologically important airway receptors, such as the prostanoid, cholinergic, or beta-adrenergic receptor. Montelukast inhibits physiologic actions of LTD 4 at the CysLT 1 receptors, without any agonist activity.
How to dose Montelukast Sodium?
Montelukast Sodium Film-Coated Tablets,10 mg, are beige, rounded square-shaped, biconvex film-coated tablets, engraved with “APO” on one side and “M10” on the other side.
Montelukast Sodium Chewable Tablets, 5 mg, are pink, round, biconvex-shaped tablets, engraved with “APO” on one side and “M5” on the other side.
Montelukast Sodium Chewable Tablets, 4 mg, are pink, oval, biconvex-shaped tablets, engraved with “APO” on one side and “M4” on the other side.
What are the side effects?
- Headaches — in up to 18.4 percent of people
- The flu — up to 4.2 percent
- Abdominal pain (stomach pain) — up to 2.9 percent
- Cough — up to 2.7 percent
- Indigestion or heartburn — up to 2.1 percent.
Storage
Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) .
Disclaimer:
Information on this page is provided for general information purposes. You should not make a clinical treatment decision based on information contained in this page without consulting other references including the package insert of the drug, textbooks and where relevant, expert opinion. We cannot be held responsible for any errors you make in administering drugs mentioned on this page, nor for use of any erroneous information contained on this page.